Plain-English translation of NCT04046497 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing an artificial intelligence smartphone app designed to help people newly diagnosed with first-episode psychosis stay on track with their oral antipsychotic medication. The app works like a digital reminder and support system that you can use on your own phone. Researchers want to see whether this tool makes it easier for people to take their medication consistently, which can help prevent relapse and reduce hospital visits.
Staying consistent with psychiatric medication is one of the biggest challenges people face after a first psychosis diagnosis, and skipping doses often leads to relapse and hospitalization. Current methods of checking whether people are taking their medication—like pill counts or pharmacy records—don't work well in real-world settings, so this study is testing whether a smartphone app could be a practical way to support medication adherence and improve outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either receive the smartphone app or to continue with your usual care. If you receive the app, you would download it onto your phone and use it to help you remember and track your daily medication doses. Researchers will follow up with all participants to see how often they go to the hospital or emergency room, and will ask those who receive the app about whether they found it helpful and easy to use.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States